Por favor, use este identificador para citar o enlazar este ítem:
https://hdl.handle.net/11000/34906
Registro completo de metadatos
Campo DC | Valor | Lengua/Idioma |
---|---|---|
dc.contributor.author | Herranz López, María | - |
dc.contributor.author | Boix Castejón, Marina | - |
dc.contributor.author | Olivares Vicente, Mariló | - |
dc.contributor.author | Campoy, Paula | - |
dc.contributor.author | Caturla, Nuria | - |
dc.contributor.author | Jones, Jonathan | - |
dc.contributor.author | Zazo, Juan M. | - |
dc.contributor.author | Roche, Enrique | - |
dc.contributor.author | Micol, Vicente | - |
dc.contributor.other | Departamentos de la UMH::Bioquímica y Biología Molecular | es_ES |
dc.date.accessioned | 2025-01-18T09:41:58Z | - |
dc.date.available | 2025-01-18T09:41:58Z | - |
dc.date.created | 2021-09 | - |
dc.identifier.citation | Journal of Functional Foods Volume 84, September 2021, 104583 | es_ES |
dc.identifier.issn | 2214-9414 | - |
dc.identifier.issn | 1756-4646 | - |
dc.identifier.uri | https://hdl.handle.net/11000/34906 | - |
dc.description.abstract | Many patients with stage 1 hypertension have difficulties to achieve lifestyle changes to avoid the progression of the disease. The use of natural alternatives with demonstrated blood pressure-regulating properties is instrumental at this stage, avoiding the side effects found in some pharmaceutical drugs. In this context, previous studies have indicated the possibility that a botanical nutraceutical product based on the combination of Lippia citriodora and Hibiscus sabdariffa extracts has hypotensive properties in overweight and obese individuals. Therefore, we aimed to evaluate the antihypertensive properties of this dietary supplement, as well as the effect on anthropometric and circulating parameters in pre-hypertensive and early stage 1 hypertensive patients (n = 84). The nutraceutical product, rich in polyphenolic compounds, has been assessed in a 6-week randomized, double-blind, placebo-controlled trial with pre-hypertensive and early stage 1 hypertensive (non-medicated) individuals. Participants consumed early in the morning in fasting conditions 2 capsules/day containing each one 250 mg of the polyphenolic extracts. Anthropometric and blood parameters as well as punctual and continuous blood pressure monitoring were determined in placebo and experimental groups. As a result and compared to baseline values, volunteers showed a significant reduction of average daily systolic/diastolic blood pressure as well as in daytime diastolic/systolic, nighttime diastolic blood pressure and in % dipper. Intergroup analysis revealed that the consumption of the plant extract resulted in a significant reduction of body fat content (− 1.26%; p < 0.05) and nocturnal systolic blood pressure (− 16.60 mmHg; p < 0.05) as well as an improvement of the dipper status (3.18%; p < 0.01). In conclusion, these results suggest that the nutraceutical acts as a main regulator of the individual’s blood pressure towards healthier values, and therefore may be useful for prehypertensive/pre-medicated individuals. | es_ES |
dc.format | application/pdf | es_ES |
dc.format.extent | 8 | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Elsevier | es_ES |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | Pre-hypertension | es_ES |
dc.subject | Continuous blood pressure monitoring | es_ES |
dc.subject | Body fat | es_ES |
dc.subject | Systolic/diastolic blood pressure | es_ES |
dc.subject | Dipper status | es_ES |
dc.subject | Polyphenols | es_ES |
dc.subject.other | CDU::5 - Ciencias puras y naturales::57 - Biología | es_ES |
dc.title | Effect of metabolaid® on pre- and stage 1 hypertensive patients: A randomized controlled trial | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.relation.publisherversion | https://doi.org/10.1016/j.jff.2021.104583 | es_ES |
Ver/Abrir:
2. EFFECT OF METABOLAID® ON PRE- AND STAGE 1 HYPERTENSIVE PATIENTS_A RANDOMIZED CONTROLLED TRIAL.pdf
790,26 kB
Adobe PDF
Compartir:
La licencia se describe como: Atribución-NonComercial-NoDerivada 4.0 Internacional.